Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Disease‐free survival · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Failure to clear liver metastases · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Recurrence of liver metastases · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Transjugular intrahepatic portosystemic shunts vs conventional treatment Health‐related quality of life · adults with hepatorenal syndrome Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Crash‐related injury rates · drivers or passengers travelling in passenger or commercial vehicles Education, incentive, and engineering‐based interventions to promote the use of seat belts (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Crash‐related mortality rates · drivers or passengers travelling in passenger or commercial vehicles Education, incentive, and engineering‐based interventions to promote the use of seat belts (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Crash‐related injury rates · drivers or passengers travelling in passenger or commercial vehicles Education, incentive, and engineering‐based interventions to promote the use of seat belts (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Crash‐related mortality rates · drivers or passengers travelling in passenger or commercial vehicles Education, incentive, and engineering‐based interventions to promote the use of seat belts (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Crash‐related injury rates · drivers or passengers travelling in passenger or commercial vehicles Education, incentive, and engineering‐based interventions to promote the use of seat belts (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Crash‐related mortality rates · drivers or passengers travelling in passenger or commercial vehicles Education, incentive, and engineering‐based interventions to promote the use of seat belts (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of participants with any bleeding ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serious infections ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Length of hospital admission ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Hospital readmission rate ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Intervention (no. of studies/participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins,… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Placebo · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins,… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Intervention (no. of studies/participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Placebo · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Intervention (no. of studies/participants) Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Placebo Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Intervention (no. of studies and participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Placebo · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Intervention (no. of studies/participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod,… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Placebo · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod,… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Intervention (no. of studies/participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Placebo · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer… Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Early vs delayed laparoscopic appendicectomy Abdominal abscess · paediatric participants with appendiceal abscess Early versus delayed appendicectomy for appendiceal phlegmon or abscess (2024) · Cochrane | no estimate extracted | NR | No studies |
Early vs delayed laparoscopic appendicectomy Faecal fistula · paediatric participants with appendiceal abscess Early versus delayed appendicectomy for appendiceal phlegmon or abscess (2024) · Cochrane | no estimate extracted | NR | No studies |
Early vs delayed laparoscopic appendicectomy Time away from normal activities (days) · paediatric participants with appendiceal abscess Early versus delayed appendicectomy for appendiceal phlegmon or abscess (2024) · Cochrane | no estimate extracted | NR | No studies |
Early vs delayed laparoscopic appendicectomy Overall morbidity · paediatric participants with appendiceal abscess Early versus delayed appendicectomy for appendiceal phlegmon or abscess (2024) · Cochrane | no estimate extracted | NR | No studies |
Early vs delayed laparoscopic appendicectomy Wound infection · paediatric participants with appendiceal abscess Early versus delayed appendicectomy for appendiceal phlegmon or abscess (2024) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin vs unfractionated heparin Major bleeding Median · adults with kidney failure treated with long‐term HD Anticoagulation for people receiving long‐term haemodialysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin vs unfractionated heparin Minor bleeding Median · adults with kidney failure treated with long‐term HD Anticoagulation for people receiving long‐term haemodialysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin vs unfractionated heparin Blood transfusion · adults with kidney failure treated with long‐term HD Anticoagulation for people receiving long‐term haemodialysis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Any psychosocial intervention vs treatment Continuous abstinence, longest · adults with stimulant use disorder Psychosocial interventions for stimulant use disorder (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin + megestrol vs megestrol Abnormal uterine bleeding ‐ not measured · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin + megestrol vs megestrol Health‐related quality of life (HRQoL) ‐ not measured · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Recurrence of endometrial hyperplasia ‐ not reported · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin vs megestrol Health‐related quality of life (HRQoL) ‐ not measured · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin vs megestrol Adverse effects during treatment ‐ not reported · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane | no estimate extracted | NR | No studies |
Mindfulness‐enhanced parent training vs parent training Measures of self‐compassion · parents of children between the ages of 0 and 18 years Mindfulness‐enhanced parenting programmes for improving the psychosocial outcomes of children (0 to 18… (2024) · Cochrane | no estimate extracted | NR | No studies |
Mindfulness‐enhanced parent training vs no‐treatment, waitlist, or attentional control Adverse effects · parents of children between the ages of 0 and 18 years Mindfulness‐enhanced parenting programmes for improving the psychosocial outcomes of children (0 to 18… (2024) · Cochrane | no estimate extracted | NR | No studies |
Mindfulness‐enhanced parent training vs no‐treatment, waitlist, or attentional control Measures of self‐compassion · parents of children between the ages of 0 and 18 years Mindfulness‐enhanced parenting programmes for improving the psychosocial outcomes of children (0 to 18… (2024) · Cochrane | no estimate extracted | NR | No studies |
Mindfulness‐enhanced parent training vs parent training Adverse effects · parents of children between the ages of 0 and 18 years Mindfulness‐enhanced parenting programmes for improving the psychosocial outcomes of children (0 to 18… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality · participants with gallstone disease (cholesterol, pigment, or mixed) Modified dietary fat intake for treatment of gallstone disease in people of any age (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serious adverse events at longest · participants with gallstone disease (cholesterol, pigment, or mixed) Modified dietary fat intake for treatment of gallstone disease in people of any age (2024) · Cochrane | no estimate extracted | NR | No studies |